Literature DB >> 19593617

Complete remission of multiple recurrent hepatocellular carcinomas by oral administration of enteric-coated tegafur/uracil in a patient with huge hepatocellular carcinoma extending to the inferior vena cava after hepatic resection: analysis of mRNA expression of fluoropyrimidine metabolism enzymes in the primary tumor.

Masanori Matsuda1, Shugo Shiba, Masami Asakawa, Hiroshi Kono, Hideki Fujii.   

Abstract

We herein report the complete remission of multiple recurrent hepatocellular carcinomas (HCCs) by the oral administration of tegafur/uracil (UFT) alone. A 56-year-old Japanese man with two huge HCCs was admitted and underwent hepatic resection. Intraoperative ultrasonography revealed that the tumor thrombus extended to the inferior vena cava (IVC) with a small tumor in the left hepatic lobe. Right trisectionectomy of the liver, removal of the tumor thrombus in the IVC, and partial resection of the left lobe were performed. Microscopic examination revealed that the larger tumor was moderately to poorly differentiated HCC and the smaller tumor was well-differentiated HCC. The small tumor in the left lobe was diagnosed as an intrahepatic metastasis of the larger tumor. Two months after the surgery, computed tomography (CT) revealed multiple HCC recurrences in the remnant liver, but complete remission was achieved by the administration of UFT alone. To clarify the reason for the good response of the recurrent HCC to UFT, the mRNA expression level of several fluoropyrimidine metabolism enzymes was measured in resected specimens. A lower expression of thymidine phosphorylase (TP) might explain the good response to UFT. The patient is alive without intra- or extrahepatic recurrence more than 6 years after the hepatic resection.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19593617     DOI: 10.1007/s10147-008-0820-0

Source DB:  PubMed          Journal:  Int J Clin Oncol        ISSN: 1341-9625            Impact factor:   3.402


  12 in total

1.  Improved survival with oral administration of enteric-coated tegafur/uracil for advanced stage IV-A hepatocellular carcinoma.

Authors:  T Ishikawa; T Ichida; S Sugitani; Y Tsuboi; T Genda; S Sugahara; K Uehara; J Inayoshi; J Yokoyama; Y Ishimoto; H Asakura
Journal:  J Gastroenterol Hepatol       Date:  2001-04       Impact factor: 4.029

2.  Quantitation of thymidylate synthase, dihydrofolate reductase, and DT-diaphorase gene expression in human tumors using the polymerase chain reaction.

Authors:  T Horikoshi; K D Danenberg; T H Stadlbauer; M Volkenandt; L C Shea; K Aigner; B Gustavsson; L Leichman; R Frösing; M Ray
Journal:  Cancer Res       Date:  1992-01-01       Impact factor: 12.701

3.  Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase.

Authors:  D Salonga; K D Danenberg; M Johnson; R Metzger; S Groshen; D D Tsao-Wei; H J Lenz; C G Leichman; L Leichman; R B Diasio; P V Danenberg
Journal:  Clin Cancer Res       Date:  2000-04       Impact factor: 12.531

4.  Sudden death from massive pulmonary tumor embolism due to hepatocellular carcinoma.

Authors:  G S Chan; W K Ng; I O Ng; P Dickens
Journal:  Forensic Sci Int       Date:  2000-02-28       Impact factor: 2.395

Review 5.  Multicentric occurrence of hepatocellular carcinoma: diagnosis and clinical significance.

Authors:  Y Matsumoto; H Fujii; M Matsuda; H Kono
Journal:  J Hepatobiliary Pancreat Surg       Date:  2001

6.  Surgical intervention for patients with stage IV-A hepatocellular carcinoma without lymph node metastasis: proposal as a standard therapy.

Authors:  I Ikai; Y Yamaoka; Y Yamamoto; N Ozaki; Y Sakai; S Satoh; N Shinkura; M Yamamoto
Journal:  Ann Surg       Date:  1998-03       Impact factor: 12.969

7.  Thymidylate synthase and dihydropyrimidine dehydrogenase mRNA expression levels: predictors for survival in colorectal cancer patients receiving adjuvant 5-fluorouracil.

Authors:  Marko Kornmann; Wolfgang Schwabe; Silvia Sander; Martina Kron; Jörn Sträter; Sucan Polat; Erika Kettner; Hans F Weiser; Wolfram Baumann; Harald Schramm; Peter Häusler; Kati Ott; Detlev Behnke; Ludger Staib; Hans G Beger; Karl H Link
Journal:  Clin Cancer Res       Date:  2003-09-15       Impact factor: 12.531

8.  Profiling of fluorouracil-related genes by microdissection technique in hepatocellular carcinoma.

Authors:  Tsubasa Takahashi; Hiroshi Yoshida; Yasuhiro Mamada; Nobuhiko Taniai; Yoshiaki Mizuguchi; Tetsuya Shimizu; Daisuke Kakinuma; Yoshinori Ishikawa; Koho Akimaru; Yuichi Sugisaki; Takashi Tajiri
Journal:  Hepatogastroenterology       Date:  2007-09

9.  Role of thymidine phosphorylase and orotate phosphoribosyltransferase mRNA expression and its ratio to dihydropyrimidine dehydrogenase in the prognosis and clinicopathological features of patients with pancreatic cancer.

Authors:  Kotaro Miyake; Satoru Imura; Tomoharu Yoshizumi; Tetsuya Ikemoto; Yuji Morine; Mitsuo Shimada
Journal:  Int J Clin Oncol       Date:  2007-04-27       Impact factor: 3.402

10.  Both gene expression for orotate phosphoribosyltransferase and its ratio to dihydropyrimidine dehydrogenase influence outcome following fluoropyrimidine-based chemotherapy for metastatic colorectal cancer.

Authors:  W Ichikawa; H Uetake; Y Shirota; H Yamada; T Takahashi; Z Nihei; K Sugihara; Y Sasaki; R Hirayama
Journal:  Br J Cancer       Date:  2003-10-20       Impact factor: 7.640

View more
  4 in total

1.  Development of a resistance-like phenotype to sorafenib by human hepatocellular carcinoma cells is reversible and can be delayed by metronomic UFT chemotherapy.

Authors:  Terence C Tang; Shan Man; Ping Xu; Giulio Francia; Kae Hashimoto; Urban Emmenegger; Robert S Kerbel
Journal:  Neoplasia       Date:  2010-11       Impact factor: 5.715

2.  Surgical treatment after hepatic arterial infusion chemotherapy for hepatocellular carcinoma extending into the right atrium.

Authors:  Shintaro Kurahashi; Tsuyoshi Sano; Seiji Natsume; Yoshiki Senda; Hidekazu Yamaura; Yoshitaka Inaba; Yasuhiro Shimizu
Journal:  Surg Case Rep       Date:  2015-06-06

3.  Clinical significance of the thymidylate synthase, dihydropyrimidine dehydrogenase, and thymidine phosphorylase mRNA expressions in hepatocellular carcinoma patients receiving 5-fluorouracil-based transarterial chemoembolization treatment.

Authors:  Hongyun Zhao; Yuanyuan Zhao; Ying Guo; Yan Huang; Suxia Lin; Cong Xue; Fei Xu; Yang Zhang; Liping Zhao; Zhihuang Hu; Li Zhang
Journal:  Onco Targets Ther       Date:  2013-07-03       Impact factor: 4.147

4.  Surgical management of hepatocellular carcinoma with tumor thrombi in the inferior vena cava or right atrium.

Authors:  Kenji Wakayama; Toshiya Kamiyama; Hideki Yokoo; Tatsuhiko Kakisaka; Hirofumi Kamachi; Yosuke Tsuruga; Kazuaki Nakanishi; Tsuyoshi Shimamura; Satoru Todo; Akinobu Taketomi
Journal:  World J Surg Oncol       Date:  2013-10-05       Impact factor: 2.754

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.